Latest Healthcare Research Reports

Tag: cancer tumor profiling market share

  • Cancer Tumor Profiling Market Growth Through 2030 Creates New Strategic Opportunities

    Cancer Tumor Profiling Market Growth Through 2030 Creates New Strategic Opportunities

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    Cancer Tumor Profiling Market Value Expansion And Long-Term Growth Outlook

    The landscape of cancer tumor profiling has experienced swift expansion, commencing from a valuation of $14.97 billion in 2025 and projecting an increase to $17.1 billion by 2026, reflecting a compound annual growth rate of 14.3%. This upward trajectory historically owes much to factors such as the heightened application of tumor biopsy diagnostics, the broadening scope of oncology research initiatives, the early integration of molecular stratification in clinical practice, the proliferation of profiling services within hospital settings, and the increasing accessibility of sophisticated laboratory facilities.

    The market for cancer tumor profiling is poised for significant expansion in the coming years, projected to reach $28.27 billion by 2030 with a compound annual growth rate of 13.4%. This anticipated surge is fueled by several key factors including a heightened need for informed precision oncology decisions, the proliferation of tailored cancer treatments, augmented investments in translational research, a greater embrace of cutting-edge sequencing technologies, and an intensified emphasis on predictive diagnostic approaches for cancer. Over the forecast period, prominent developments are expected to include a more widespread application of multi-omics profiling of tumors, increased utilization of targeted sequencing panels, deeper integration of artificial intelligence in analyzing biomarkers, broader availability of personalized treatment strategies, and a more pronounced focus on prognostic profiling.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

    #Cancer Tumor Profiling Market Growth Drivers And Industry Catalysts

    The escalating worldwide prevalence of cancer is anticipated to fuel the expansion of the market for cancer and tumor profiling. Cancer, characterized by the uncontrolled proliferation and dissemination of abnormal cells, sees a corresponding rise in the need for sophisticated profiling techniques as its incidence grows, aiding clinicians in assessing disease severity. For illustration, figures from the American Cancer Society in 2024 indicated that 2 million new cancer diagnoses were made in the United States, an increase from the 1.9 million recorded in 2023. Consequently, this broader trend of rising cancer cases globally is a primary catalyst for the advancing cancer and tumor profiling market.

    ## Cancer Tumor Profiling Market Driver: Growing Incidence Of Stomach Cancer

    An upward trend in stomach cancer cases is poised to stimulate the expansion of the cancer and tumor profiling market. Stomach cancer manifests as the uncontrolled proliferation of malignant cells within the stomach’s lining. Although gastrointestinal stromal tumors (GISTs) can arise in the stomach, they represent a separate entity from stomach cancer itself. Research has indicated that individuals diagnosed with GISTs, particularly when two distinct tumors merge, face a heightened susceptibility to developing other forms of cancer, such as adenocarcinoma of the small intestine. Cancer and tumor profiling offer crucial insights into the development of stomach cancer, thereby facilitating more effective treatment strategies. As an example, Cancer Research UK, a prominent UK-based cancer research charity, forecasts a 12% decline in stomach cancer incidence in the United Kingdom from the 2023-2025 period to the 2038-2040 period, estimating an average of 8 cases per 100,000 individuals annually. Therefore, the increasing occurrence of stomach cancer is a significant driver for the growth of the cancer and tumor profiling market.

    Cancer Tumor Profiling Market Segment Landscape: Which Areas Lead Market Development?

    The cancer tumor profiling market covered in this report is segmented –

    1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types

    2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies

    3) By Process Type: Genomics, Proteomics, Epigenetics, Other Types

    4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications

    Subsegments:

    1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)

    2) By Breast Cancer: Hormone Receptor-Positive, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer

    3) By Colorectal Cancer: Colon Cancer, Rectal Cancer

    4) By Prostate Cancer: Localized Prostate Cancer, Advanced Prostate Cancer

    5) By Melanoma: Cutaneous Melanoma, Non-Cutaneous Melanoma

    6) By Ovarian Cancer: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer

    7) By Stomach Cancer: Gastric Adenocarcinoma, Gastrointestinal Stromal Tumors (GISTs)

    8) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Neuroendocrine Tumors

    9) By Thyroid Cancer: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer

    10) By Other Cancer Types: Kidney Cancer, Bladder Cancer, Liver Cancer, Esophageal Cancer

    Cancer Tumor Profiling Market Industry Leaders And Market Competition

    Major companies operating in the cancer tumor profiling market are F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, OncoDNA, Strata Oncology Inc., RareCyte Inc., Inivata Limited, Cepheid

    Access The Complete Cancer Tumor Profiling Market Report:

    https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

    Cancer Tumor Profiling Market Regional Distribution: Which Areas Drive Market Expansion?

    North Americawas the largest region in cancer and tumor profiling market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Rising Incidences Of Cancer Across Globe Is Affecting The Direction Of The Cancer Tumor Profiling Market

    Rising Incidences Of Cancer Across Globe Is Affecting The Direction Of The Cancer Tumor Profiling Market

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Is The Market Value Of The Cancer Tumor Profiling Market Projected To Expand During 2026–2030?

    The candida infection testing market has shown substantial growth over recent years. It is anticipated to expand from $16.72 billion in 2025 to $17.8 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. This historical expansion can be linked to a rise in fungal infection cases, the expanding number of immunocompromised individuals, the enhancement of diagnostic services in hospitals, the implementation of culture-based methods for fungal testing, and growing recognition of antifungal resistance.

    The market for candida infection testing is poised for significant expansion in the coming years. This market is projected to reach $22.56 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.1%. This anticipated growth is driven by several factors, including the rising need for swift fungal diagnostic solutions, the growing integration of molecular and microbiome testing, the broadening availability of point-of-care fungal tests, increasing financial commitments to infectious disease diagnostics, and a heightened emphasis on individualized antifungal treatments. Key trends anticipated during this period encompass the growing acceptance of molecular techniques for candida detection, the increased utilization of rapid NAAT-based testing, the expanding incorporation of microbiome analysis, the proliferation of hospital-centric fungal diagnostics, and an intensified drive towards the early detection of fungal infections.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

    What Influential Factors Are Boosting The Cancer Tumor Profiling Market Demand?

    The projected expansion of the candida infection testing market is fueled by the rising occurrence of yeast infections. These infections are fungal in nature, stemming from an excessive proliferation of candida, frequently manifesting in regions like the mouth, genitals, and skin, and typically leading to symptoms such as itching, redness, and discomfort. The main triggers for yeast infections include an abundance of the candida fungus, frequently linked to disruptions in the body’s bacterial balance, compromised immune defenses, or shifts in hormonal levels. To precisely identify the presence of candida overgrowth in such cases, candida infection testing is employed, aiding medical professionals in confirming the condition and determining suitable therapeutic approaches. An illustrative example comes from May 2025, where the UK Health Security Agency, a UK-based government public health body, reported a 4% increase in yeast-related bloodstream infections in England in 2024 versus 2023, escalating from 2,170 to 2,247 reports, with the rate climbing from 3.8 to 3.9 per 100,000 population during that timeframe. Consequently, the escalating frequency of yeast infections is set to stimulate the expansion of the candida infection testing market.

    How Are Different Segment Groups Identified Within The Cancer Tumor Profiling Market?

    The cancer tumor profiling market covered in this report is segmented –

    1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types

    2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies

    3) By Process Type: Genomics, Proteomics, Epigenetics, Other Types

    4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications

    Subsegments:

    1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)

    2) By Breast Cancer: Hormone Receptor-Positive, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer

    3) By Colorectal Cancer: Colon Cancer, Rectal Cancer

    4) By Prostate Cancer: Localized Prostate Cancer, Advanced Prostate Cancer

    5) By Melanoma: Cutaneous Melanoma, Non-Cutaneous Melanoma

    6) By Ovarian Cancer: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer

    7) By Stomach Cancer: Gastric Adenocarcinoma, Gastrointestinal Stromal Tumors (GISTs)

    8) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Neuroendocrine Tumors

    9) By Thyroid Cancer: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer

    10) By Other Cancer Types: Kidney Cancer, Bladder Cancer, Liver Cancer, Esophageal Cancer

    Which Trends Are Influencing The Expansion Of The Cancer Tumor Profiling Market?

    Companies operating in the candida infection testing market are concentrating on developing technologically advanced solutions, such as fully automated PCR rapid tests for candida detection, to improve diagnostic precision and enhance patient outcomes. A fully automated PCR rapid test for detecting candida is a sophisticated diagnostic instrument that employs polymerase chain reaction (PCR) technology to quickly and accurately identify Candida species in clinical samples. For instance, in May 2024, Bosch Healthcare Solutions GmbH, a Germany-based medical technology manufacturer, introduced a PCR test for candida auris detection on the Vivalytic platform, providing fully automated, rapid testing within an hour at the point of care. This advanced test enables prompt screenings and stands in sharp contrast to traditional culture methods, which typically require one to three days in centralized labs, leading to delays in diagnosis and treatment. Developed for clinical environments, the test is especially advantageous for high-risk patients, allowing for timely diagnosis and intervention to combat the serious health risks associated with C. auris infections.

    Who Are The Firms Contributing To The Cancer Tumor Profiling Market Ecosystem?

    Major companies operating in the cancer tumor profiling market are F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, OncoDNA, Strata Oncology Inc., RareCyte Inc., Inivata Limited, Cepheid

    Access The Complete Cancer Tumor Profiling Market Report:

    https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

    What Is The Largest Regional Market In The Cancer Tumor Profiling Market?

    North America was the largest region in cancer and tumor profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Cancer Tumor Profiling Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp

    Browse Through More Reports Similar to the Global Cancer Tumor Profiling Market 2026, By The Business Research Company

    Community Oncology Services Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

    Oncology Drugs Market 2026

    https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

    Cancer Supportive Care Drugs Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cancer-supportive-care-drugs-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Tumor profiling market forecast with key trends

    Tumor profiling market forecast with key trends

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Anticipated Rise In Market Value Of The Cancer Tumor Profiling Market During The Forecast Period?

    The cancer tumor profiling market size has seen substantial expansion in recent years. It is projected to increase from $14.97 billion in 2025 to $17.1 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.3%. This historical growth can be attributed to several factors including the increasing utilization of tumor biopsy testing, the expansion of oncology research programs, the early clinical adoption of molecular stratification, the growth of hospital-based profiling services, and the rising availability of advanced laboratory infrastructure.

    The cancer tumor profiling market size is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $28.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.4%. This anticipated growth during the forecast period stems from factors such as an escalating need for precision oncology decision-making, the widening scope of personalized cancer therapies, increasing capital directed towards translational research, the growing uptake of advanced sequencing technologies, and a heightened emphasis on predictive oncology diagnostics. Key developments expected during this period involve the rising application of multi-omics tumor profiling, the increasing acceptance of targeted sequencing panels, the expanding incorporation of AI-driven biomarker analysis, the broader development of personalized treatment planning, and an intensified focus on prognostic profiling.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

    What Key Drivers Are Fueling The Growth Of The Cancer Tumor Profiling Market?

    The global increase in cancer cases is anticipated to drive forward the cancer and tumor profiling market. Cancer is a condition where certain body cells become excessively large and multiply without control, spreading to other parts of the body. As the number of individuals diagnosed with cancer rises, so does the demand for cancer tumor profiling, which enables medical professionals to ascertain the disease’s severity. For example, in 2024, the American Cancer Society, a US-based professional organization, reported that 2 million new cancer cases were diagnosed in the country, an increase from 1.9 million new cases in 2023. Consequently, the escalating worldwide incidences of cancer are fueling the growth of the cancer and tumor profiling market. The expanding occurrence of stomach cancer is expected to propel the growth of the cancer and tumor profiling market in the future. Stomach cancer refers to the unrestrained multiplication and growth of malignant cells within the stomach’s lining. While gastrointestinal stromal tumors (GISTs) can develop in the stomach, they are distinct from stomach cancer. When two separate tumors collide and merge into one, patients with GISTs have been observed to have an elevated risk of developing additional cancers, including small bowel adenocarcinoma. Cancer and tumor profiling offers insights into the development of cancer in the stomach, aiding in the provision of better treatment. For instance, according to Cancer Research UK, a UK-based independent cancer research organization, the incidence of stomach cancer in the UK is projected to fall by 12% between 2023-2025 and 2038-2040, reaching an average of 8 cases per 100,000 people each year. Therefore, the growing incidence of stomach cancer is driving the growth of the cancer and tumor profiling market.

    What Are The Key Segment Divisions In The Cancer Tumor Profiling Market Segment Structure?

    The cancer tumor profiling market covered in this report is segmented –

    1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types

    2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies

    3) By Process Type: Genomics, Proteomics, Epigenetics, Other Types

    4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications

    Subsegments:

    1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)

    2) By Breast Cancer: Hormone Receptor-Positive, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer

    3) By Colorectal Cancer: Colon Cancer, Rectal Cancer

    4) By Prostate Cancer: Localized Prostate Cancer, Advanced Prostate Cancer

    5) By Melanoma: Cutaneous Melanoma, Non-Cutaneous Melanoma

    6) By Ovarian Cancer: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer

    7) By Stomach Cancer: Gastric Adenocarcinoma, Gastrointestinal Stromal Tumors (GISTs)

    8) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Neuroendocrine Tumors

    9) By Thyroid Cancer: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer

    10) By Other Cancer Types: Kidney Cancer, Bladder Cancer, Liver Cancer, Esophageal Cancer

    Which Organizations Are Engaged In The Cancer Tumor Profiling Market?

    Major companies operating in the cancer tumor profiling market are F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, OncoDNA, Strata Oncology Inc., RareCyte Inc., Inivata Limited, Cepheid

    Get The Full Cancer Tumor Profiling Market Report:

    https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

    Which Region Holds The Highest Market Share In The Cancer Tumor Profiling Market?

    North America was the largest region in cancer and tumor profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Cancer Tumor Profiling Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

    Browse Through More Reports Similar to the Global Cancer Tumor Profiling Market 2026, By The Business Research Company

    Cancer Diagnostics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

    Cancer Profiling Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

    Cancer Biomarker Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Cancer Tumor Profiling Industry Trends and Market Growth Forecast for 2026–2030

    Global Cancer Tumor Profiling Industry Trends and Market Growth Forecast for 2026–2030

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Market Value Is Expected For The Cancer Tumor Profiling Market At The End Of The 2026–2030 Forecast Period?

    The cancer tumor profiling market has demonstrated rapid expansion in recent years. It is projected to increase from $14.97 billion in 2025 to $17.1 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.3%. This historical growth can be linked to several factors including the increased adoption of tumor biopsy testing, the expansion of oncology research programs, the early clinical application of molecular stratification, the proliferation of hospital-based profiling services, and the enhanced availability of sophisticated laboratory infrastructure.

    The cancer tumor profiling market is projected to undergo significant expansion in the coming years. It is forecast to achieve a valuation of $28.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.4%. This projected growth throughout the forecast period stems from factors such as the increasing necessity for precision oncology decision-making, the broadening scope of personalized cancer therapies, rising investments in translational research, the increasing adoption of advanced sequencing technologies, and an elevated focus on predictive oncology diagnostics. Noteworthy trends anticipated during this period include a greater deployment of multi-omics tumor profiling, a surge in the uptake of targeted sequencing panels, the expanding integration of AI-powered biomarker analysis, the wider implementation of personalized treatment planning, and an intensified emphasis on prognostic profiling.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

    What Drivers Are Shaping The Future Growth Of The Cancer Tumor Profiling Market?

    The rising global prevalence of cancer is anticipated to fuel the expansion of the cancer and tumor profiling market in the future. Cancer is characterized by the uncontrolled proliferation and dissemination of certain body cells. With the increasing occurrence of cancer, there is a corresponding surge in the need for cancer tumor profiling, a method used by medical professionals to assess disease progression. For example, in 2024, the American Cancer Society, a US-based professional organization, documented 2 million new cancer diagnoses in the US, an increase from 1.9 million new cases in 2023. Consequently, the growing global incidence of cancer is a key driver for the cancer and tumor profiling market. Cancer Tumor Profiling Market Driver: Growing Incidence Of Stomach Cancer

    The escalating occurrence of stomach cancer is set to boost the expansion of the cancer and tumor profiling market in the foreseeable future. Stomach cancer involves the unregulated division and spread of cancerous cells within the stomach’s inner lining. While gastrointestinal stromal tumors (GISTs) can manifest in the stomach, they are a separate condition from stomach cancer. Patients with GISTs have shown a heightened propensity for developing other cancers, such as small bowel adenocarcinoma, when two distinct tumors converge. Cancer and tumor profiling offers crucial data on stomach cancer progression, aiding in more effective treatment strategies. For instance, Cancer Research UK, an independent cancer research body based in the UK, anticipates a 12% reduction in stomach cancer incidence in the UK, dropping to 8 cases per 100,000 people annually on average, between the periods of 2023-2025 and 2038-2040. Consequently, the rising incidence of stomach cancer fuels the growth of the cancer and tumor profiling market.

    What Segment Types Make Up The Cancer Tumor Profiling Market?

    The cancer tumor profiling market covered in this report is segmented –

    1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types

    2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies

    3) By Process Type: Genomics, Proteomics, Epigenetics, Other Types

    4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications

    Subsegments:

    1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)

    2) By Breast Cancer: Hormone Receptor-Positive, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer

    3) By Colorectal Cancer: Colon Cancer, Rectal Cancer

    4) By Prostate Cancer: Localized Prostate Cancer, Advanced Prostate Cancer

    5) By Melanoma: Cutaneous Melanoma, Non-Cutaneous Melanoma

    6) By Ovarian Cancer: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer

    7) By Stomach Cancer: Gastric Adenocarcinoma, Gastrointestinal Stromal Tumors (GISTs)

    8) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Neuroendocrine Tumors

    9) By Thyroid Cancer: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer

    10) By Other Cancer Types: Kidney Cancer, Bladder Cancer, Liver Cancer, Esophageal Cancer

    Who Are The Key Players Driving Competition In The Cancer Tumor Profiling Market?

    Major companies operating in the cancer tumor profiling market are F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, OncoDNA, Strata Oncology Inc., RareCyte Inc., Inivata Limited, Cepheid

    Read the full cancer tumor profiling market report here:

    https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

    Which Geographic Regions Are Influencing Demand In The Cancer Tumor Profiling Market?

    North America was the largest region in cancer and tumor profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Cancer Tumor Profiling Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp

    Browse Through More Reports Similar to the Global Cancer Tumor Profiling Market 2026, By The Business Research Company

    Community Oncology Services Global Market Report

    https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

    Oncology Drugs Market

    https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

    Cancer Supportive Care Drugs Global Market Report

    https://www.thebusinessresearchcompany.com/report/cancer-supportive-care-drugs-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Cancer Tumor Profiling Market Forecast 2026: Where the Industry Is Headed

    Cancer Tumor Profiling Market Forecast 2026: Where the Industry Is Headed

    Uncover key drivers, emerging technologies, and competitive movements shaping the cancer tumor profiling market from 2026–2035 with trusted insights from The Business Research Company

    What are the forecasted starting (2026) and ending (2030) market sizes for the Cancer Tumor Profiling Market?

    The cancer tumor profiling market size has experienced rapid expansion in recent years. Projections indicate it will expand from $14.97 billion in 2025 to $17.1 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.3%. Historically, this market’s expansion was driven by several factors, including the increased adoption of tumor biopsy testing, the broadening of oncology research initiatives, the early integration of molecular stratification in clinical settings, the rise of hospital-based profiling offerings, and the enhanced availability of sophisticated laboratory infrastructure.

    The cancer tumor profiling market size is anticipated to experience substantial growth in the coming years. It is projected to expand to $28.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.4%. This growth during the forecast period can be attributed to several factors, including the increasing demand for precision oncology decision-making, the expansion of personalized cancer therapies, growing investments in translational research, the rising adoption of advanced sequencing technologies, and an increasing focus on predictive oncology diagnostics. Major trends identified for the forecast period encompass the increasing use of multi-omics tumor profiling, the rising adoption of targeted sequencing panels, the growing integration of AI-driven biomarker analysis, the expansion of personalized treatment planning, and an enhanced focus on prognostic profiling.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

    What Drivers Are Supporting Technological Adoption In The Cancer Tumor Profiling Market?

    A rising global occurrence of cancer is projected to fuel the expansion of the cancer and tumor profiling market. This condition involves the unchecked proliferation of specific body cells that subsequently disseminate to other regions. The growing count of cancer diagnoses correlates with an increased need for cancer tumor profiling, a tool that assists medical professionals in assessing disease severity. For example, in 2024, the American Cancer Society, a US-based professional organization, documented 2 million new cancer cases in the country, an increase from 1.9 million new cases in 2023. Consequently, the growing global incidence of cancer is a primary catalyst for the development of the cancer and tumor profiling market.

    What Segment Types Are Examined In The Cancer Tumor Profiling Market?

    The cancer tumor profiling market covered in this report is segmented –

    1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types

    2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies

    3) By Process Type: Genomics, Proteomics, Epigenetics, Other Types

    4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications

    Subsegments:

    1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)

    2) By Breast Cancer: Hormone Receptor-Positive, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer

    3) By Colorectal Cancer: Colon Cancer, Rectal Cancer

    4) By Prostate Cancer: Localized Prostate Cancer, Advanced Prostate Cancer

    5) By Melanoma: Cutaneous Melanoma, Non-Cutaneous Melanoma

    6) By Ovarian Cancer: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer

    7) By Stomach Cancer: Gastric Adenocarcinoma, Gastrointestinal Stromal Tumors (GISTs)

    8) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Neuroendocrine Tumors

    9) By Thyroid Cancer: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer

    10) By Other Cancer Types: Kidney Cancer, Bladder Cancer, Liver Cancer, Esophageal Cancer

    Who Are The Primary Competitors In The Global Cancer Tumor Profiling Market?

    Major companies operating in the cancer tumor profiling market are F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, OncoDNA, Strata Oncology Inc., RareCyte Inc., Inivata Limited, Cepheid

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

    Which Global Regions Are Shaping The Competitive Landscape Of The Cancer Tumor Profiling Market?

    North America was the largest region in cancer and tumor profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Cancer Tumor Profiling Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp

    Browse Through More Reports Similar to the Global Cancer Tumor Profiling Market 2026, By The Business Research Company

    Cancer Diagnostics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

    Cancer Profiling Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

    Cancer Biomarker Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Cancer Tumor Profiling Market Size, Share & Trends Analysis Report By Product | Forecast to 2029

    Cancer Tumor Profiling Market Size, Share & Trends Analysis Report By Product | Forecast to 2029

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    How Will The Cancer Tumor Profiling Market Valuation Change Between Now And 2029?

    In recent times, the market size of cancer tumor profiling has seen a significant expansion. There is an expected increase from $13 billion in 2024 to $14.97 billion in 2025, showing a compound annual growth rate (CAGR) of 15.1%. The spike during the historical span can be linked to factors such as a rise in cancer cases, advancements in precision medicine initiatives and research partnerships, enhancements in cancer diagnosis and early detection techniques, the offering of diverse targeted therapy choices, and favorable regulations for cancer profiling examinations.

    Over the next few years, the cancer tumor profiling market is slated for swift expansion, rocketing to $25.12 billion by 2029 with a compound annual growth rate (CAGR) of 13.8%. This predicted surge is due to factors such as the unfolding of immunotherapy and immunoprofiling in cancer treatment, progression in liquid biopsy and non-invasive tumor profiling techniques, along with the wider use of single-cell sequencing for comprehensive tumor insights. Other contributing factors include broadening of cancer screening and early diagnosis programs, and a growing need for profiling of rare and particular cancer subtypes. The forecast period is also expected to witness several trends like the incorporation of tumor profiling into everyday clinical practices, advancements in multi-omics strategies, harnessing artificial intelligence (AI) and machine learning for data interpretation, personalized medicine and targeted treatment evolution, and progress in genomics and next-generation sequencing (ngs) technologies.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

    What Underlying Factors Are Supporting The Cancer Tumor Profiling Market Growth?

    The surge in cancer cases worldwide is anticipated to stimulate the expansion of the cancer and tumor profiling market in the future. Cancer is a medical condition that causes a rampant and uncontrolled growth of certain cells which subsequently invades other parts of the body. With the escalating prevalence of cancer, comes a growing need for cancer tumor profiling that allows medical practitioners to accurately ascertain the extent and gravity of the disease. For example, the American Cancer Society, a professional organization based in the US, recorded an increase in cancer diagnoses from 1.9 million new cases in 2023 to 2 million new cases in 2024. Accordingly, the uptrend in global cancer occurrences fuels the development of the cancer and tumor profiling market.

    Which Sub-Segments Are Driving Growth Within The Cancer Tumor Profiling Market?

    The cancer tumor profilingmarket covered in this report is segmented –

    1) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Ovarian Cancer; Stomach Cancer; Pancreatic Cancer; Thyroid Cancer; Other Cancer Types

    2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); In Situ Hybridization (ISH); Microarray; Other Technologies

    3) By Process Type: Genomics; Proteomics; Epigenetics; Metabolomics; Other Types

    4) By Application: Personalized Medicine; Diagnostics; Biomarker Discovery; Prognostics; Research Applications

    Subsegments:

    1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)

    2) By Breast Cancer: Hormone Receptor-Positive; Triple-Negative Breast Cancer; HER2-Positive Breast Cancer

    3) By Colorectal Cancer: Colon Cancer; Rectal Cancer

    4) By Prostate Cancer: Localized Prostate Cancer; Advanced Prostate Cancer

    5) By Melanoma: Cutaneous Melanoma; Non-Cutaneous Melanoma

    6) By Ovarian Cancer: Epithelial Ovarian Cancer; Non-Epithelial Ovarian Cancer

    7) By Stomach Cancer: Gastric Adenocarcinoma; Gastrointestinal Stromal Tumors (GISTs)

    8) By Pancreatic Cancer: Exocrine Pancreatic Cancer; Neuroendocrine Tumors

    9) By Thyroid Cancer: Papillary Thyroid Cancer; Follicular Thyroid Cancer; Medullary Thyroid Cancer

    10) By Other Cancer Types: Kidney Cancer; Bladder Cancer; Liver Cancer; Esophageal Cancer

    What Future-Focused Trends Are Anticipated In The Cancer Tumor Profiling Market?

    A notable trend that is emerging with increased prominence in the cancer and tumor profiling market is the heightened focus on research and development activities. Major players in this industry, such as the German company QIAGEN N.V which specialises in sample and assay technology for fields like applied testing, pharmaceutical development, molecular diagnostics and academic research, are keen on strengthening their position by answering consumer demands through rigorous R&D. For example, the company recently announced the Conformitè Europëenne (CE)-marking and commercialization of therascreen PIK3CA RGQ PCR Kit in Europe. This tool is aimed to help in identifying breast cancer patients with PIK3CA mutations. It is essentially a diagnostic assay for detecting an activating mutation in the gene named phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) and is the first of its kind to allow testing from either DNA from plasma specimens or FFPE tissue.

    Which Companies Hold A Competitive Edge In The 11 Market?

    Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

    Which Region Dominates The Cancer Tumor Profiling Market Today?

    North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp

    Browse Through More Reports Similar to the Global Cancer Tumor Profiling Market 2025, By The Business Research Company

    Cancer Biologics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

    Cancer Diagnostics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

    Tumor Ablation Therapy Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/tumor-ablation-therapy-devices-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Cancer Tumor Profiling Market Analysis 2025–2029: Opportunities for Strategic Growth

    Global Cancer Tumor Profiling Market Analysis 2025–2029: Opportunities for Strategic Growth

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    How Much Larger Is The Cancer Tumor Profiling Market Expected To Become By 2029 Compared With Its 2025 Level?

    The cancer tumor profiling market size has seen rapid growth in recent years. It is expected to expand from $13 billion in 2024 to $14.97 billion in 2025, achieving a compound annual growth rate (CAGR) of 15.1%. This historic period’s growth can be attributed to factors such as increasing cancer incidence, the expansion of precision medicine initiatives and research collaborations, enhancements in cancer diagnostics and early detection methods, the availability of diverse targeted therapy options, and supportive regulatory frameworks for cancer profiling tests.

    The cancer tumor profiling market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $25.12 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 13.8%. Key drivers for this growth during the forecast period include the broader application of immunotherapy and immunoprofiling in cancer therapies, the advancement of liquid biopsy and non-invasive tumor profiling techniques, the utilization of single-cell sequencing for in-depth tumor analysis, the spread of cancer screening and early detection initiatives, and a rising need for profiling rare and orphan cancer subtypes. Significant trends expected in the same period encompass the incorporation of tumor profiling into standard clinical procedures, breakthroughs in multi-omics methodologies, the integration of artificial intelligence (AI) and machine learning for data interpretation, the evolution of personalized medicine and targeted therapies, and ongoing progress in genomics and next-generation sequencing (NGS) technologies.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

    Which Drivers Are Supporting Growth Of The Cancer Tumor Profiling Market?

    The global rise in cancer occurrences is projected to stimulate the future expansion of the cancer and tumor profiling market. Cancer is defined as a condition where certain body cells multiply without restraint and spread to different parts of the body. With an increasing number of cancer diagnoses, the need for cancer tumor profiling also escalates, as it assists medical professionals in assessing the disease’s severity. For example, in 2024, the American Cancer Society, a professional organization based in the US, reported 2 million new cancer cases diagnosed in the country, an increase from 1.9 million new cases in 2023. Therefore, the growing worldwide prevalence of cancer is driving the growth of the cancer and tumor profiling market.

    What Are The Segment Types Shaping The Cancer Tumor Profiling Market?

    The cancer tumor profilingmarket covered in this report is segmented –

    1) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Ovarian Cancer; Stomach Cancer; Pancreatic Cancer; Thyroid Cancer; Other Cancer Types

    2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); In Situ Hybridization (ISH); Microarray; Other Technologies

    3) By Process Type: Genomics; Proteomics; Epigenetics; Metabolomics; Other Types

    4) By Application: Personalized Medicine; Diagnostics; Biomarker Discovery; Prognostics; Research Applications

    Subsegments:

    1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)

    2) By Breast Cancer: Hormone Receptor-Positive; Triple-Negative Breast Cancer; HER2-Positive Breast Cancer

    3) By Colorectal Cancer: Colon Cancer; Rectal Cancer

    4) By Prostate Cancer: Localized Prostate Cancer; Advanced Prostate Cancer

    5) By Melanoma: Cutaneous Melanoma; Non-Cutaneous Melanoma

    6) By Ovarian Cancer: Epithelial Ovarian Cancer; Non-Epithelial Ovarian Cancer

    7) By Stomach Cancer: Gastric Adenocarcinoma; Gastrointestinal Stromal Tumors (GISTs)

    8) By Pancreatic Cancer: Exocrine Pancreatic Cancer; Neuroendocrine Tumors

    9) By Thyroid Cancer: Papillary Thyroid Cancer; Follicular Thyroid Cancer; Medullary Thyroid Cancer

    10) By Other Cancer Types: Kidney Cancer; Bladder Cancer; Liver Cancer; Esophageal Cancer

    What Long-Term Trends Will Shape The Future Growth Of The Cancer Tumor Profiling Industry?

    Increasing research and development activities have emerged as a prominent trend gaining traction in the cancer and tumor profiling market. Major companies operating within the cancer and tumor profiling sector are prioritizing research and development efforts to address consumer demand and solidify their market position. For instance, QIAGEN N.V., a German company specializing in sample and assay technology for applied testing, pharmaceutical development, molecular diagnostics, and academic research, announced the Conformitè Europëenne (CE)-marking and commercialization of its therascreen PIK3CA RGQ PCR Kit in Europe. This kit is intended as a tool to assist in identifying breast cancer patients with PIK3CA mutations. The therascreen PIK3CA test functions as a diagnostic assay for detecting an activating mutation in the phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) gene, and it is the first to enable testing of DNA from both plasma specimens or FFPE tissue.

    Which Leading Players Are Enhancing Their Cancer Tumor Profiling Market Presence Worldwide?

    Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

    Which Region Shows The Highest Potential For Future Expansion In The Cancer Tumor Profiling Market?

    North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Request A Customized Version Of The Cancer Tumor Profiling Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp

    Browse Through More Reports Similar to the Global Cancer Tumor Profiling Market 2025, By The Business Research Company

    Cancer Biologics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

    Cancer Diagnostics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

    Tumor Ablation Therapy Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/tumor-ablation-therapy-devices-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • From Insight to Impact: Strategic Growth Mapping in the Cancer Tumor Profiling Market

    From Insight to Impact: Strategic Growth Mapping in the Cancer Tumor Profiling Market

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Are the Key Projections for the CAGR of the Cancer Tumor Profiling Market Size From 2025 to 2034?

    The market size for cancer tumor profiling has experienced swift growth lately. The market is expected to expand from $13 billion in 2024 to $14.97 billion in 2025, with a compound annual growth rate (CAGR) of 15.1%. The development during the historic period can be linked to a surge in cancer cases, progression in precision medicine initiatives and research partnerships, advancements in cancer diagnostics and early detection techniques, the presence of an extensive variety of targeted therapy choices, and favorable regulatory structures for cancer profiling examinations.

    The market for cancer tumor profiling is set to experience a substantial expansion in the coming years. The market is predicted to reach$25.12 billion in 2029″, with a CAGR of 13.8%. This projected growth is largely due to the broader incorporation of immunotherapy and immunoprofiling in cancer treatments, advanced liquid biopsy and non-invasive methods for tumor profiling, the application of single-cell sequencing for enhanced tumor detailing, the enlargement of cancer screening and early detection programs, and an ascending demand for the profiling of rare and orphan cancer subtypes. Some prominent trends for the forecasted period include the incorporation of tumor profiling in regular clinical procedures, advancements in multi-omic strategies, the use of AI and machine learning in data interpretation, the development of personalized medication and targeted treatments, and progress in genomics and next-generation sequencing technologies.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

    What are the Fundamental Drivers and Innovations Shaping the Cancer Tumor Profiling Market?

    The escalating number of cancer occurrences worldwide are anticipated to bolster the expansion of the cancer and tumor profiling market. Cancer is characterized by the abnormal growth of some body cells which then invade other parts of the body. With the surge in cancer instances, the need for cancer tumor profiling escalates as it enables medical professionals to assess the disease’s intensity. For example, the US-based American Cancer Society reported an increase in diagnosed cancer cases from 1.9 million in 2023 to 2 million in 2024. Consequently, the rising global cancer occurrences fuel the expansion of the cancer and tumor profiling market.

    How Is the Cancer Tumor Profiling Market Segmented?

    The cancer tumor profilingmarket covered in this report is segmented –

    1) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Ovarian Cancer; Stomach Cancer; Pancreatic Cancer; Thyroid Cancer; Other Cancer Types

    2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); In Situ Hybridization (ISH); Microarray; Other Technologies

    3) By Process Type: Genomics; Proteomics; Epigenetics; Metabolomics; Other Types

    4) By Application: Personalized Medicine; Diagnostics; Biomarker Discovery; Prognostics; Research Applications

    Subsegments:

    1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)

    2) By Breast Cancer: Hormone Receptor-Positive; Triple-Negative Breast Cancer; HER2-Positive Breast Cancer

    3) By Colorectal Cancer: Colon Cancer; Rectal Cancer

    4) By Prostate Cancer: Localized Prostate Cancer; Advanced Prostate Cancer

    5) By Melanoma: Cutaneous Melanoma; Non-Cutaneous Melanoma

    6) By Ovarian Cancer: Epithelial Ovarian Cancer; Non-Epithelial Ovarian Cancer

    7) By Stomach Cancer: Gastric Adenocarcinoma; Gastrointestinal Stromal Tumors (GISTs)

    8) By Pancreatic Cancer: Exocrine Pancreatic Cancer; Neuroendocrine Tumors

    9) By Thyroid Cancer: Papillary Thyroid Cancer; Follicular Thyroid Cancer; Medullary Thyroid Cancer

    10) By Other Cancer Types: Kidney Cancer; Bladder Cancer; Liver Cancer; Esophageal Cancer

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp

    Which Regions Are Driving the Next Phase of the Cancer Tumor Profiling Market Growth?

    North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    What Key Trends Are Shaping the Future of the Cancer Tumor Profiling Market?

    Heightened research and development activities are becoming a prominent trend in the cancer and tumor profiling market. The leading firms in this sector are concentrating their efforts on these activities as a means to fulfill consumer needs and consolidate their market position. Take, for example, QIAGEN N.V, a German corporation that creates sample and assay technology for various fields, including applied testing, pharmaceutical advancement, molecular diagnostics, and academic studies. They have recently announced the CE-marking and commercial introduction of therascreen PIK3CA RGQ PCR Kit in Europe. This tool is instrumental in identifying patients with PIK3CA mutations in breast cancer. Touted as the first diagnostic assay to allow testing of DNA from both plasma specimens and FFPE tissue, the therascreen PIK3CA test distinctively identifies an activating mutation in the phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) gene.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

    How Is the Cancer Tumor Profiling Market Defined and What Are Its Core Parameters?

    Cancer tumor profiling refers to a laboratory test that examines a sample of tumor tissue for specific genes, gene mutations (changes), proteins, or other biomarkers. Tumor profiling can help with treatment planning as well as predicting if cancer will recur or spread to other parts of the body.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6053

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Cancer Tumor Profiling Market to Reach $25.33 Billion by 2029 | Key Drivers and Future Outlook

    Cancer Tumor Profiling Market to Reach $25.33 Billion by 2029 | Key Drivers and Future Outlook

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Growth Rate of the Cancer Tumor Profiling Market?

    The market size for cancer tumor profiling has seen a significant expansion in the recent past. It is set to grow from a value of $13 billion in 2024 to a larger value of $14.99 billion in 2025, experiencing a compound annual growth rate (CAGR) of 15.3%. The surge in numbers during the historic period is linked with the rising incidence of cancer, advancements in precision medicine initiatives and research partnerships, enhanced cancer diagnostic techniques and early detection methodologies, an abundance of targeted therapy alternatives, and a favorable regulatory environment for cancer profiling examinations.

    What Growth Rate Is Forecasted for the Cancer Tumor Profiling Market by 2029?

    The market size of cancer tumor profiling is predicted to experience significant growth in the forthcoming years, increasing to $25.33 billion in 2029 with a compound annual growth rate (CAGR) of 14.0%. The projected rise is attributable to the broader implementation of immunotherapy and immunoprofiling in cancer treatment, advancements in liquid biopsy and non-invasive tumor profiling techniques, the employment of single-cell sequencing for comprehensive tumor profiling, growth in cancer screening and early detection initiatives, and heightened demand for the profiling of rare and orphan cancer subtypes. Key trends for the forecast period feature the incorporation of tumor profiling into standard clinical procedures, progress in multi-omics methodologies, the application of artificial intelligence (AI) and machine learning in data interpretation, tailoring of medicine and treatment based on individual needs, and progression in genomics and next-generation sequencing (NGS) technologies.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

    Which Key Companies Are Shaping the Future of the Cancer Tumor Profiling Market?

    Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid

    Which Factors Are Driving Demand in the Cancer Tumor Profiling Industry?

    The global surge in cancer cases is anticipated to fuel the expansion of the cancer and tumor profiling market. Cancer, a condition characterized by uncontrolled cell growth and spread, is seeing a rise in prevalence, triggering an increased demand for cancer tumor profiling. This technique helps physicians assess the disease’s severity. For example, in 2024, the American Cancer Society, based in the US, disclosed that cancer diagnoses rose to 2 million from 1.9 million in the previous year. Consequently, the escalating frequency of cancer worldwide propels the progress of the cancer and tumor profiling market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp

    How Is the Cancer Tumor Profiling Market Segmented by Several Divisions?

    The cancer tumor profiling market covered in this report is segmented –

    1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types

    2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies

    3) By Process Type: Genomics, Proteomics, Epigenetics, Metabolomics, Other Types

    4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications

    Subsegments:

    1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)

    2) By Breast Cancer: Hormone Receptor-Positive, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer

    3) By Colorectal Cancer: Colon Cancer, Rectal Cancer

    4) By Prostate Cancer: Localized Prostate Cancer, Advanced Prostate Cancer

    5) By Melanoma: Cutaneous Melanoma, Non-Cutaneous Melanoma

    6) By Ovarian Cancer: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer

    7) By Stomach Cancer: Gastric Adenocarcinoma, Gastrointestinal Stromal Tumors (GISTs)

    8) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Neuroendocrine Tumors

    9) By Thyroid Cancer: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer

    10) By Other Cancer Types: Kidney Cancer, Bladder Cancer, Liver Cancer, Esophageal Cancer

    What are the Emerging Market Trends Driving the Growth of the Cancer Tumor Profiling Industry?

    The escalating activities in research and development are emerging as a leading trend in the cancer and tumor profiling market. Leading companies in the sector are investing heavily in research and development in order to satisfy consumer demands and solidify their market position. For example, QIAGEN N.V, a German firm specializing in sample and assay technology for applied testing, pharmaceutical development, molecular diagnostics, and academic research recently announced the Conformitè Europëenne (CE) – marking and commercial rollout of their therascreen PIK3CA RGQ PCR Kit in Europe. This kit is designed to assist in identifying breast cancer patients with PIK3CA mutations. The therascreen PIK3CA test is a diagnostic tool for the detection of an activating mutation in the phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) gene, and it’s the first to permit testing of DNA from either plasma specimens or FFPE tissue.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

    Which Regions Are Driving Growth in the Cancer Tumor Profiling Market?

    North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6053

    This Report Delivers Insight On:

    1. How big is the cancer tumor profiling market, and how is it changing globally?

    2. Who are the major companies in the cancer tumor profiling market, and how are they performing?

    3. What are the key opportunities and risks in the cancer tumor profiling market right now?

    4. Which products or customer segments are growing the most in the cancer tumor profiling market?

    5. What factors are helping or slowing down the growth of the cancer tumor profiling market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • $25.33 Billion Forecast for Cancer Tumor Profiling Market by 2029, Backed by Demand and Innovation

    $25.33 Billion Forecast for Cancer Tumor Profiling Market by 2029, Backed by Demand and Innovation

    Discover trends, market shifts, and competitive outlooks for the cancer tumor profiling industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

    #What Is the Current and Projected Market Size of the Cancer Tumor Profiling Market Through 2034?

    The market size for cancer tumor profiling has experienced swift expansion in the past few years. The market valuation is projected to increase from $13 billion in 2024 to $14.99 billion in 2025, marking a compound annual growth rate (CAGR) of 15.3%. This growth during the historical period is credited to factors such as the escalating incidences of cancer, advancements in precision medicine initiatives and research collaborations, enhancements in cancer diagnostics and early detection techniques, the accessibility of numerous targeted therapy options, and favorable regulatory structures for cancer profiling tests.

    Anticipations are high for a substantial proliferation in the size of the cancer tumor profiling market over the upcoming years, with predictions suggesting it will reach a value of $25.33 billion in 2029, equating to a compound annual growth rate (CAGR) of 14.0%. This projected expansion during the forecast period is linked to the widespread use of immunotherapy and immunoprofiling in cancer treatment, advancements in non-invasive tumor profiling and liquid biopsy methods, the incorporation of single-cell sequencing for in-depth tumor analysis, increased emphasis on cancer screening and early detection programs, and the heightened demand for profiling of rare and orphan cancer subtypes. The forecast period is also set to see key trends such as the standardization of tumor profiling in everyday clinical practices, advancements in multi-omics approaches, inclusion of artificial intelligence (AI) and machine learning in data interpretation, developments in precision medicine and targeted therapies, as well as improvements in genomics and next-generation sequencing (NGS) technologies.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

    What Are the Core Growth Drivers Propelling the Cancer Tumor Profiling Market Forward?

    The escalating occurrences of cancer worldwide are predicted to drive the expansion of the cancer and tumor profiling market. Cancer, a condition marked by uncontrolled cell growth and spreading across the body, elevates the need for cancer tumor profiling, which allows physicians to assess disease severity. For example, the American Cancer Society, a professional organization based in the US, documented 2 million fresh cancer diagnoses in 2024, a rise from 1.9 million new instances in 2023. Thus, the growing prevalence of cancer globally fuels the development of the cancer and tumor profiling market.

    What Segment Types Define the Cancer Tumor Profiling Market Structure?

    The cancer tumor profiling market covered in this report is segmented –

    1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types

    2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies

    3) By Process Type: Genomics, Proteomics, Epigenetics, Metabolomics, Other Types

    4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications

    Subsegments:

    1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)

    2) By Breast Cancer: Hormone Receptor-Positive, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer

    3) By Colorectal Cancer: Colon Cancer, Rectal Cancer

    4) By Prostate Cancer: Localized Prostate Cancer, Advanced Prostate Cancer

    5) By Melanoma: Cutaneous Melanoma, Non-Cutaneous Melanoma

    6) By Ovarian Cancer: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer

    7) By Stomach Cancer: Gastric Adenocarcinoma, Gastrointestinal Stromal Tumors (GISTs)

    8) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Neuroendocrine Tumors

    9) By Thyroid Cancer: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer

    10) By Other Cancer Types: Kidney Cancer, Bladder Cancer, Liver Cancer, Esophageal Cancer

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp

    Which Geographic Areas Hold the Strongest Growth Potential in the Cancer Tumor Profiling Market?

    North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Which Emerging Trends that Are Influencing theCancer Tumor Profiling Industry Evolution?

    A rising trend in the cancer and tumor profiling market has been identified as extensive research and development activities. Prominent businesses in this sector, such as the Germany-based QIAGEN N.V., are investing heavily in these areas to satisfy client needs and cement their standing in the market. An example of this is their recent introduction of the therascreen PIK3CA RGQ PCR Kit in Europe, having been granted the necessary Conformitè Europëenne (CE) mark. The Kit is aimed at detecting breast cancer patients with PIK3CA mutations, providing a diagnostic assay for the detection of this mutation in the PIK3CA gene. This assay tests for DNA in plasma samples or FFPE tissue, a first in its kind.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

    What Is the Definition of the Cancer Tumor Profiling Market?

    Cancer tumor profiling refers to a laboratory test that examines a sample of tumor tissue for specific genes, gene mutations (changes), proteins, or other biomarkers. Tumor profiling can help with treatment planning as well as predicting if cancer will recur or spread to other parts of the body.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6053

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model